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AbsTrACT
Objectives To investigate whether people with age-
related macular degeneration (AMD) are able to self-detect 
symptoms and, if so, what symptoms they experience, 
from whom they first seek help, whether help is sought 
within the 1 week recommended by the Royal College of 
Ophthalmologists’ guidelines and reasons for any delay.
Methods and analysis A retrospective, cross-
sectional survey design. Postal surveys were sent to 4000 
members of the UK Macular Society. Inclusion criteria were 
participants aged >50 years at diagnosis of AMD with 
diagnosis after August 2008; criteria were met by 621 
respondents. The main outcome was reasons for delays in 
diagnosis for wet AMD. Data were analysed using χ2 and 
conventional content analysis.
results Only one third (n=199; 32%) of respondents 
were able to self-detect symptoms. In line with national 
guidance, over half (n=131; 64%) of those self-detecting 
symptoms sought help promptly. For those whose initial 
diagnosis was delayed more than 1 week, 27% had 
potentially treatable wet AMD requiring urgent treatment to 
prevent vision loss. Reasons for delay reflected individual 
& service-related issues, including AMD not being detected 
in the initial consultation, and individuals not perceiving the 
urgency for symptom investigation.
Conclusion In practice most patients sought help 
within 1 week; however, potentially sight-damaging delays 
occurred from symptom onset to diagnosis. Suggestions 
for reducing delay include increasing population 
awareness of AMD symptoms, the need for urgent 
detection and close monitoring for AMD and signposting 
patients to appropriate support services to ensure prompt 
detection of any future signs of wet AMD.
InTrOduCTIOn
Age-related macular degeneration (AMD) is 
the leading cause of severe visual impairment 
in older adults.1 Late-stage AMD accounts for 
two thirds of registrations of visual impair-
ment or blindness in the UK.1 The estimated 
UK prevalence for 2010 was 513 000 cases of 
late-stage AMD, which is expected to rise to 
679 000 by 2020.2 There is some debate about 
whether AMD symptoms can be self-detected 
satisfactorily at an early stage. The guidelines 
of the Royal College of Ophthalmologists 
(RCOphth) (2013)1 suggested patients with 
symptoms of dry AMD may not be able to 
self-detect symptoms. Consequently these may 
only be detected by a professional on routine 
examination. However, when both eyes are 
affected, patients commonly report deteri-
oration in central vision and difficulty with 
daily activities (eg. reading). Patients with 
wet or neovascular AMD may report blurred 
central vision, distorted vision (including 
straight lines appearing wavy (metamorpho-
psia)) or missing patches (scotomas) in their 
central vision. When both eyes are affected, 
patients are more likely to lose their ability to 
read, drive or see fine details including facial 
expressions. However, having good vision in 
one eye may mask difficulties in the other 
eye.3 There has been little research exam-
ining how patients identify and describe the 
symptoms that lead them to seek help.
There is mounting evidence that treatment 
outcomes for wet AMD, including visual acuity 
Key messages
 ► Previous research has shown symptoms of age-re-
lated macular degeneration (AMD) can be difficult to 
self-detect. There are delays from symptom onset 
to diagnosis despite findings that early help seeking 
leads to better treatment outcomes (eg, visual acu-
ity) in wet AMD.
 ► This study shows that most patients seek help with-
in 1 week but delays occur between symptom onset 
and diagnosis, which reflect individual & service-re-
lated issues.
 ► This paper provides a unique insight into patient-re-
ported reasons for delays including delays obtaining 
appointments, AMD not being detected in the initial 
consultation and patients not perceiving the urgency 
of prompt help-seeking for their symptoms.
 ► Suggestions for reducing delay and shaping clinical 
practice are provided, including increasing patient 
and practitioner awareness of AMD symptoms, the 
urgency of detecting and close monitoring for AMD 
(particularly following treatment for other eye condi-
tions) and educating patients alongside signposting 
to support services to ensure prompt detection of 
any future signs of wet AMD, following the diagnos-
tic consultation.
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Figure 1 Flowchart of respondents included in analysis. 
AMD, age-related macular degeneration. *The reasons for 
the stratified recruitment listed earlier are explained within 
the main text.
(VA), can be improved by early diagnosis and treatment4 
. Patients with better pre-treatment VA have been shown 
to have better VA outcomes following anti-vascular endo-
thelial growth factor (VEGF) treatment (ranibizumab or 
bevacizumab) for wet AMD, with the effects holding up to 
1 year later.5 Furthermore, having symptoms of AMD less 
than a month before starting treatment has been associated 
with better post-treatment VA than having the symptoms 
for a longer duration before treatment.6 Hence there are 
significant benefits to early help seeking and detection of 
wet AMD. The benefit of early detection of dry AMD is less 
clear as there is currently no treatment available, other 
than the age-related eye disease study (AREDS) nutri-
tional supplement formulation, which slows progression of 
dry AMD.7 However, as dry AMD can turn into wet AMD, 
educating patients on the use of Amsler grid to self-mon-
itor for indications of further deterioration or possible 
conversion to wet AMD and encouraging lifestyle changes, 
such as smoking cessation, may help to reduce the risk of 
dry or wet AMD progression.3
In practice, patients who have advanced AMD in one 
eye are encouraged to seek help from an optometrist or 
hospital eye service as soon as possible, once symptoms 
in the second eye are noticed.1 In addition, healthcare 
professionals (HCPs) are encouraged to provide advice 
to, and follow-up, patients with earlier stages of AMD in 
a timely way. The RCOphth guidelines1 recommend that 
patients with suspected wet AMD are referred by optome-
trists to a fast track macular clinic within a week, and have 
treatment commenced in no more than one additional 
week. This is further reinforced in the 2018 National 
Institute for Health and Care Excellence (NICE) AMD 
guidelines, which recommended that treatment for wet 
AMD be commenced within 14 days of first presentation/
diagnosis.8 Since 2009, optometrists have been advised 
to make direct referrals to the fast track macular clinics 
for suspected cases of wet AMD, rather than via the 
general practitioner (GP). Research suggests, however, 
that these guidelines have not always been followed in 
practice, with ongoing delays occurring from symptom 
detection to diagnosis.9 Among patients with wet AMD, 
the mean duration from symptom onset to assessment 
has been found to be around 2 months, with delays being 
longer for older patients aged over 75 years than younger 
patients.9 10 To the authors’ knowledge reasons for such 
delays have not previously been reported.
This study investigated the diagnostic experiences of a 
UK-wide sample of Macular Society members with AMD, 
including how their AMD (wet or dry) was first noticed, 
the symptom(s) that led them to seek help, the time taken 
and reasons for any delay. This study offers a unique 
insight into patient-reported symptoms and reasons for 
delay, with important implications for clinical practice.
MeThOds
Participants
A total of 4000 Macular Society members were selected 
from those who had joined the Society after 1 January 
2000, using campaign management software (NFP 
CARE, Advanced Computer Software Group). In order to 
achieve an adequate sample size to investigate the impact 
of the RCOphth guidelines, stratified sampling was used, 
based on the date of joining the Macular Society (see 
figure 1). The reasons for this stratification are described 
elsewhere.11
The main inclusion criteria were diagnosis with AMD 
after August 2008 (the date when NICE guidelines12 were 
published recommending early use of anti-VEGF injec-
tions for wet AMD and early help seeking and diagnosis 
became important) and age at diagnosis over 50 years 
(the diagnostic cut-off for AMD).12
Measures
The Macular Society survey 2013, used to collect the 
present data, asked respondents about several aspects 
of their experiences of living with a macular condition. 
Development work on the questionnaire and data from 
other parts of this survey are reported elsewhere.11 This 
paper focuses on the time around diagnosis. Several 
questions were designed to focus on:
 ► How the respondent’s condition was first noticed, 
and if by themselves or someone else.
 ► From whom they first sought help.
 ► The symptom that led them to seek help (free-text 
response).
 ► How quickly they sought advice from a HCP once 
symptoms were noticed.
 ► If their appointment was delayed by more than 2 days, 
the reason(s) why (free text-response).
Sociodemographic information (sex, age, whether 
they lived alone) was collected, alongside whether they 
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Table 1 Respondent characteristics (n=621)
Variables Frequency/n
Sex
  Female/male 428/192
  Not specified 1
Age at diagnosis
Mean years (range) 76.6 (50–97)
Type of AMD
  Wet AMD 245
  Dry AMD 246
  Both wet and dry AMD 63
  Not specified 67
Previous awareness of AMD
  Yes 259
  No 356
  Not specified 6
General health status
  Good, very good, excellent 453
  Neither good nor bad 127
  Bad, very bad, extremely bad 36
  Not specified 5
Living alone
  Yes 275
  No 341
  Not specified 5
AMD, age-related macular degeneration.
had heard of macular conditions before their diagnosis, 
self-rated health status, and eye-related information 
(diagnostic type, date of diagnosis).
Patient involvement
The Macular Society survey 2013 was adapted from a 
previous survey sent to members of the Society in 1999. 
The 1999 survey was pilot tested with people with AMD, 
to understand their experiences and priorities regarding 
the management of their condition. The Society funded 
and supported both surveys. Findings from both surveys 
have been reported to members in meetings of the 
Society and in their publications, SideView and Digest and 
elsewhere.13
Procedure
Informed consent was gained by receipt of a signed infor-
mation/consent sheet attached to the survey.
The Macular Society survey 2013 was posted to 4000 
members of the Society in November 2013. The survey 
was printed in large text and telephone-interview 
completion was offered to ensure that those who were 
severely sight impaired could participate. Twenty-six 
respondents requested telephone-interview completion: 
all were conducted by EB. No prompts were used in the 
telephone interviews so that this method of comple-
tion matched paper completion as much as possible; 
however, clarification about the meaning of questions 
was provided if needed. No follow-up reminders were 
sent to respondents in order to preserve confidentiality 
and avoid possible confusion for those who had already 
completed the survey.
data analysis
Conventional content analysis14 was conducted to 
convert the free-text comments for symptoms and 
reasons for delay into numerical data. Data were 
analysed in IBM SPSS V.20. For the reasons-for-delay 
responses a coding framework was developed by AP and 
EB. These responses were coded by both researchers 
(75%), with the remaining responses coded by AP. For 
the symptom responses a coding framework was devel-
oped by AP and WMA. All responses were then coded by 
both researchers. Any discrepancies were discussed and 
resolved. Where multiple reasons/symptoms were given, 
multiple codes were allocated. These codes were then 
sorted into broader subthemes and themes and reviewed 
before being named and defined. Quotes, illustrating 
each theme, are provided in the results.
χ2 analyses were conducted to examine whether differ-
ences between respondents in reported time taken to 
seek help were associated with age, sex, health status, 
whether they lived alone and previous awareness of AMD. 
For these analyses, time to seek help was re-categorised 
into 0–6 days or ≥1 week as the RCOphth guidelines1 
recommend patients seek help within 1 week. Age was 
re-categorised into 2 groups of 50–75 years and ≥76 years, 
as previous research suggested there are longer delays for 
those >75 years; overall health status was re-categorised 
into three groups: (i) excellent to good, (ii) neither good 
nor bad, and (iii) bad to extremely bad.
Missing data
There were varying amounts of missing data among the 
outcome variables, the greatest being for reason for delay 
in the appointment with a HCP about symptoms (missing 
n=43, 30.7%). There were no suitable variables to allow 
imputation of these missing values. Sample size for each 
analysis will vary slightly depending on item non-response 
and the missing n for each variable is provided within the 
results and table 1.
resulTs
sample characteristics
Responses were received from 1571 members (response 
rate=39%) of whom 621 matched the sub-study inclusion 
criteria. For full respondent characteristics see table 1. 
The most common reason given for non-completion was 
old age, followed by ill health of members.
detection of symptoms and seeking help
Of 621 respondents, 612 answered how their macular 
condition was first noticed: 368 by their optometrist, 
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Figure 2 Who first noticed respondent’s macular 
condition?. *‘Someone else’ responses included the hospital 
eye specialist during consultation for another eye condition 
(n=34) and the GP (n=1); two respondents giving ‘other’ 
responses left the free-text response blank.
Figure 3 Time to seek help once symptoms first noticed.
Figure 4 Time to seek help once symptoms first noticed; 
sorted by age-related macular degeneration type at 
diagnosis.
199 themselves and 32 by someone else, while five ticked 
‘other’ and eight ticked two options (see figure 2). 
‘Someone else’ and ‘other’ responses included the 
hospital eye specialist during consultation for another 
eye condition and the GP.
For respondents who reported that the symptoms (or 
signs) were first noticed by themselves, by ‘someone else’ 
or ‘other’ (n=236), 230 indicated where they first sought 
help (127 optometrist, 51 hospital eye clinic, 35 GP, 6 
other and 11 ticked two options).
A total of 206 reported the time it took for them to 
seek help (including 66 same or next day, 65 2–6 days, 53 
1 week–1 month, 22 more than 1 month) (see figure 3). 
Those experiencing a delay of more than 1 week included 
19 (of 67) respondents with wet AMD, and 5 (of 21) with 
both wet and dry AMD (see figure 4).
There was a significant association between time taken 
to seek help and sex (χ2 (1, n=206)=3.848, p=0.050) with 
women being almost twice as likely as men to seek help 
within 0–6 days (OR=1.84). There was also a significant 
association between time to seek help and the type of 
AMD at diagnosis (χ2 (1, n=182)=8.78, p=0.003), with 
respondents having wet AMD being twice as likely as 
those with dry AMD to seek help in 0–6 days (OR=2.72). 
There was no significant association between time to seek 
help and respondents’ age, previous awareness of AMD, 
general health status or living alone.
symptoms
Symptom(s) leading to help-seeking were reported by 
217 respondents: for a full list, and respondent quotes 
see table 2.
The most common symptom cited as a reason for help 
seeking for patients with either type of AMD was visual 
distortion (n=87) (eg. straight lines becoming distorted). 
The second most cited symptom was deterioration in 
vision (n=83) (eg. blurred vision, loss of VA or difficulty 
focusing), which some attributed to difficulty with their 
current spectacles. Patients with either type of AMD 
reported help seeking action because AMD symptoms led 
to difficulty carrying out activities (n=34) or because they 
experienced central-field defects (scotomas) (n=34). 
Central-field defects (including black spots, blind spots 
or loss of central vision) were primarily reported by 
respondents with wet AMD.
Nineteen respondents listed symptoms that were 
not indicative of AMD, including eye discomfort/pain, 
double vision, shadows in vision, flashing lights or a tran-
sient loss of vision. In addition patients with wet AMD 
reported misattributing symptoms of AMD to another eye 
condition (n=13), namely cataracts, glaucoma or an eye 
infection, more often than patients with dry AMD. Two 
other symptoms listed by patients in both groups were 
difficulty with dark adaption (n=11) and problems with 
far vision/judging depth (n=6). Finally, additional symp-
toms included loss of chromatic sensitivity with certain 
colours disappearing (n=6) or witnessing no improve-
ment following treatment for another eye condition 
(n=3). Fear of blindness was reported by two respondents 
(n=2) who had dry AMD.
reasons for delay
Reasons for delay in having the appointment about symp-
toms were reported by 97 respondents: for a full list and 
supporting quotes see table 3. Patients reported delay 
from symptom onset to formal diagnosis and referred 
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Table 2 Symptoms that led to help seeking. Listed in rank order (n=217)
Theme Subtheme Quote
Visual distortion
(n=87/217)
(wet=62, dry=18, not 
specified=7)
Distorted vision
(n=22)
(w)‘started to notice distortion in left eye vision’#52
(d)‘I noticed distortion around edges of things & blurring of faces etc.’#669
Distorted/wavy lines
(n=65)
(d)‘I saw wavy lines where I knew it should be straight for example, door frames 
etc.’ #70
(w)‘noticed tiled floor in bathroom had wavy lines when viewed from right eye…’ 
#191
Deterioration/loss of 
visual acuity
(n=83/217)
(wet=47, dry=19, not 
specified=17)
Blurred vision
(n=45)
(d)‘slightly blurred vision and difficulty in reading road signs etc’#979
(w)’blurred vision generally’ #804
Deterioration in vision
(n=20)
(d)‘finding my sight had deteriorated too much to drive my car’ #1001
(w)‘I noticed a slight general deterioration in my sight- thought I may need new 
glasses.’ #637
Loss of vision
(n=8)
(n/s)‘overnight sudden loss of vision’ #1409
(w)’loss of vision when reading…’ #1092
Loss of visual acuity
(n=10)
(n/s)‘sight was not as sharp and did not focus properly’ #178
(w)’…didn’t have clarity of vision’ #989
Difficulty with activities 
due to AMD symptoms
(n=34/217)
(wet=15, dry=17, not 
specified=2)
Difficulty with activities 
including reading, facial 
recognition, writing and 
driving.
(d)‘unable to read a notice at a hospital visit, which made me go & seek advice’ 
#685
(w)‘I was unable to see to read or write and had to be shown where to sign a 
cheque’ #1076
(w)‘I could not judge traffic when driving one day’#295
(d)‘not able to distinguish people’#986
Central-field defects 
(scotomas)
(n=34/217)
(wet=23, dry=6, not 
specified=5)
Black spots
(n=25)
(n/s)‘I had a black patch in the centre of my left eye’ #119
(w)’saw black patches on white wall’ #715
Blind spots
(n=4)
(d)‘became aware of blind spots for example, knew the chair facing me had 2 
arms but could only see one’ #818
(w)‘Noticed broken up images in left eye.’ #726
Loss of central vision
(n=5)
(w)‘central vision in right eye disappeared’ #254
Symptoms not indicative 
of AMD
(n=19/217)
(wet=13, dry=2, not 
specified=4)
Including discomfort/
pain in eyes, eyes didn’t 
line up, double vision, 
transient loss of vision, 
black web across vision, 
shadows in vision and 
flashing lights.
(d)‘my eyes were sore…’ #1275
(w)‘…my eyes didn’t line up properly’ #571
(w)‘double vision’ #902
(w)‘loss of sight on waking for 1 min…’ #441
(w)‘I noticed a big black circle in my eye like a spiders web’ #1393
(d)‘grey shadows across my vision (left eye)’ #619
Symptoms misattributed 
to another eye condition
(n=13/217)
(wet=9, dry=3, not 
specified=1)
(w)‘…At first I therefore thought it was a cataract and deemed ok to leave for a 
while’ #413
(n/s)‘thought it was connected to the glaucoma’ #956
(w)‘sudden alteration of vision in left eye- thought initially was an eye infection’ 
#894
Difficulty with dark 
adaptation/glare
(n=11/217)
(wet=7, dry=4)
Poor dark adaptation
(n=7)
(d)‘difficulty seeing in dark situations. See a white object in a poor light but 
unable to see it to pick it up…’ #987
(w)‘eyes took a long while to adjust to different lighting conditions’#168
Increased glare
(n=4)
(w)‘whilst driving at night street lights & car lights seemed twice normal size at a 
distance’ #682
(d)‘eyes were light sensitive’ #384
#number = respondent ID code.
This table includes the themes cited by >6 respondents.
(d), respondent with dry AMD; (n/s), not specified; (w), respondent with wet AMD.
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Table 3 Reasons for delay to diagnosis. Listed in rank order (n=97)
Theme Subtheme Quote
Delay due to lack of 
appointments, facilities 
or staff
(n=45/97)
(wet=29, dry=9, not 
specified=7)
Delay getting appointment 
with HCP
(n=39)
Delay getting appointment 
due to lack of facilities
(n=6)
(w)‘My GP referred me to an eye specialist but my appointment was not for 6 
weeks’ #1133
(d)‘waited for appointment with consultant at Royal Eye Infirmary…’ #474
(w)‘Optician had no scanner (I think) & immediately sent his suspicions up to our 
crowded- RSCH, with a personal note.’ #1506
(w)‘It was Easter+I did not think to go to a hospital on a Sunday’ #1009
AMD was not detected/
labelled in the initial 
consultation
(n=30/97)
(wet=14, dry=13, not 
specified=3)
Wait and see approach to 
symptoms
(n=2)
 
HCP did not detect/label 
AMD in initial consultation
(n=20)
 
 
AMD not spotted until 
cataract removal (n=8)
(d)‘thought I was imagining the impairment?’ #1269
 
 
(d)‘for 2 years at routine annual check-ups I told the young women I thought I had 
blind spots… the next year I made a list of symptoms and gave it to the optician, 
an older more experienced man.’ #818
(w)‘The optician at Specsavers told me I had cataracts and sent me home to get 
worse and I got a lot worse v quickly…’#48
(w)‘not until cataract removed that diagnosed with MD’#13
Patient did not attribute 
symptoms to AMD
(n=20/97)
(wet=14, dry=5, not 
specified=1)
Patient lacked knowledge 
about symptoms of AMD
(n=4)
Patient attributed symptoms 
to another eye problem
(n=15)
Patient lacked knowledge of 
perceived risk for developing 
AMD
(n=1)
(w)‘I was not aware of Macular conditions affecting eyes…’#1102
(w)‘I thought that perhaps I had scratched the eye or similar’ #28
(d)‘thought I just needed stronger glasses’.#870
(w)’I had heard of AMD… thought it only affected people older than myself’#995
Referral delay due to 
being passed between 
HCPs
(n=17/97)
(wet=13, dry=2, not 
specified=2)
Being passed between HCPs 
(n=17)
(w)‘two months later I saw my GP who referred me back to the optician and the 
hospital’#315
(d)‘told by optician would send letter to doctors & up to them if they referred or not 
to hospital’ #669
Patient did not perceive 
symptoms as urgent or 
important
(n=13/97)
(wet=7, dry=3, not 
specified=3)
Patient didn't realise urgency 
of early help seeking for 
symptoms
(n=4)
Patient didn’t perceive 
seriousness/ importance of 
symptoms
(n=9)
(d)‘I had a regular yearly eye appt due a few weeks ahead’#1144
(w)’church steeples were crooked for some time but it was moving white lines in 
road when driving that made me seek help’#51
(w)‘I didn’t realise it could be serious and thought I (would) just check at the 
opticians’ #571
(d)‘did not think it important’ #987
Patient unavailable to 
make early appointment 
due to personal reasons
(n=11/97)
(wet=9, dry=1, not 
specified=1)
Patient was busy/unavailable 
to book early appointment
(n=8)
Other health conditions/family 
health took precedence
(n=3)
(w)‘I was on holiday in 2009 in Scotland, when discomfort started…’ #605
(w)‘Also I had quite serious health problems at the same time (Heart+Thyroid/
overactive)’ #1102
(d)‘my husband was ill, he needed me as I was his full time carer…’ #1396
Patient told ‘nothing can 
be done’(n=8/97)
(wet=2, dry=4, not 
specified=2)
HCP said nothing can be 
done
(n=5)
 
HCP told patient to 
monitor their eyes/make an 
appointment
(n=3)
(d)‘I have never had an appointment with the … clinic, I have been refused and told 
there is nothing they can do’. #1063
(w)‘…told that I had not been referred to the hospital… although the optician had 
in fact recognised wet AMD “because of the data protection act”’#48
 
(n/s)‘…and had not been told to do anything but to look at a card regularly in case 
it got worse’ #60
Continued
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Theme Subtheme Quote
HCP did not perceive 
AMD symptoms as urgent
(n=7/97)
(wet=4, not specified=3)
HCP did not realise/stress 
urgency of early help seeking 
for AMD symptoms
(w)‘The optician said I only had slight signs of MD- not to worry as it was normal at 
my age’ #1076
Delay getting appointment 
due to issues with 
correspondence
(n=6/97)
(wet=5, not specified=1)
(w)‘I did not see a specialist for 10 weeks…letters getting “lost” in the system’ #81
(w)‘I did not receive an appt at the eye clinic for four weeks as they had sent my 
appt to the wrong address’ #732
#number= respondent ID code.
This table includes the themes cited by ≥6 respondents.
(d), respondent with dry AMD; (n/s), not specified; (w), respondent with wet AMD.
Table 3 Continued
to delays in getting an initial appointment with various 
professionals, including the hospital eye specialist, GP 
and optometrist, as well as delays in subsequent appoint-
ments at the macular clinic.
Service/healthcare professional-related factors
The most commonly cited reasons for delay in their first 
ophthalmologist assessment among respondents with 
either type of AMD related to inability to get an earlier 
appointment ((n=39): with the hospital (n=28), GP (n=2) 
or optometrist (n=9)), or AMD not being detected or 
labelled as such in the initial consultation ((n=30): by the 
hospital eye specialist (n=6), by the GP (n=7) and by the 
optometrist (n=17)). Delay in obtaining an appointment 
was more commonly reported by those with wet AMD. 
Respondents who reported that AMD was not detected/
labelled at the consultation (similarly split between those 
with wet/dry AMD) often reported leaving the consul-
tation unclear as to whether they had AMD, resulting in 
further delay to receiving a diagnosis. For some the diag-
nosis was missed ((n=20): by the hospital eye specialist 
(n=2), by the GP (n=4) and by the optometrist (n=14)) or 
only detected following cataract removal (n=8). Another 
commonly cited reason for delay, particularly among 
those with wet AMD, was delayed referral due to being 
passed between HCPs (n=4) or referred to the hospital 
via the GP (n=13) despite guidance15 that optometrists 
should refer directly to hospital.
Other patients, including two with wet AMD, were told 
that ‘nothing could be done’, were refused a further 
appointment, or asked to make their own follow-up 
appointments at a later date resulting in a delayed diag-
nosis ((n=8): by the hospital eye specialist (n=4), by the 
GP (n=1) and by the optometrist (n=3)). Several respon-
dents including four with wet AMD, reported that they 
felt their HCP did not realise or stress the urgency of 
help seeking for AMD symptoms ((n=7): by the hospital 
eye specialist (n=3), GP (n=2) and the optometrist 
(n=2)). This led to delayed communication with other 
HCPs or the respondent feeling there was no urgency in 
following up their symptoms. Some respondents with wet 
AMD (n=6) cited delays in getting an appointment due 
to issues with correspondence (eg. appointment letters 
being lost or arriving after the offered appointment). 
Finally several respondents reported that they assumed 
waiting over 1 week for an appointment was normal NHS 
procedure (n=4).
Patient-related factors
The most common patient-related factor cited, primarily 
by patients with wet AMD, was that they did not attribute 
their symptoms to AMD as they either lacked knowledge 
about AMD symptoms and their risk for developing the 
condition, or attributed their symptoms to another eye 
problem (eg. needing stronger spectacles) (n=20). In 
addition several respondents, most commonly those with 
wet AMD, did not perceive their symptoms as urgent 
or important (n=13): such patients waited until their 
next routine appointment or until symptoms worsened 
before seeking help. Some respondents, predominantly 
those with wet AMD, reported inability to make an early 
appointment because they were too busy, on holiday, 
or had other health conditions or their family’s health 
taking precedence (n=11). One respondent with dry 
AMD reported not seeking help initially because of the 
shock about symptoms. These factors are summarised in 
table 3.
dIsCussIOn
This study found that only a third of patients were able 
to self-detect AMD signs/symptoms while the majority 
were detected by an optometrist. This finding supported 
the RCOphth guidelines, which suggested that AMD 
symptoms are often subtle and difficult to self-detect.1 
Common symptoms experienced particularly among 
those with wet AMD were distorted vision, deteriora-
tion/loss of vision including blurred vision and central 
field defects/scotomas, in line with previous findings.16 
Interestingly, however, we noted overlap in symptoms 
reported by those with wet and dry AMD and that it 
was often only when symptoms interfered with patients’ 
activities that they sought help. Most respondents who 
self-detected symptoms first sought help from their 
optometrist (56%). The majority of respondents (64%) 
sought help within the recommended time frame of 
1 week.1 Women and those diagnosed with wet AMD were 
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more likely to seek help within the recommended time 
frame. However, there was a delay in diagnosis for 36% of 
patients, including 27% with wet AMD with consequent 
risk of sight loss. For those reporting their first appoint-
ment with an HCP was delayed for more than 2 days after 
first noticing symptoms, reasons for delay reflected indi-
vidual/service-related issues, most commonly difficulties 
obtaining appointments, AMD not being detected in the 
initial consultation and, particularly for those with wet 
AMD, respondents not attributing their symptoms to 
AMD.
This is the first large-scale nationwide study to examine 
the help seeking behaviours of patients with wet and/or 
dry AMD, including questions about how AMD was first 
detected, initial symptoms, the time taken to seek help 
and reasons for any delay. Furthermore this study is one 
of the first to obtain qualitative data on the symptoms 
and reasons for delay patients report. The response rate 
of 39% was low, but not dissimilar to other recent surveys 
including a Macular Society survey in 2014 (response 
rate=31%).17Analysis was conducted with single vari-
ables; therefore, there is the possibility of confounding 
by variables which may have been related to each other 
or unmeasured such as VA, which, although beyond 
the scope of this paper, are important to acknowledge, 
and may benefit from future research. The sample was 
self-selecting and may, therefore, have included those 
whose experiences differed from the wider population 
of people with AMD. As reported elsewhere, 76% of the 
total sample responding to the 2013 Macular Society 
survey were satisfied with the diagnostic consultation.11 
It may be that those who were dissatisfied with the diag-
nostic consultation experienced more delays in diagnosis 
and/or treatment and were less likely to complete the 
survey. In addition Macular Society members may be a 
more proactive group than the population as a whole and 
perhaps likely to seek help and obtain support earlier. 
These possible sources of bias may influence the external 
validity of the findings. Nevertheless, there was still 
delay in help-seeking for initial symptoms, which several 
respondents attributed to a lack of knowledge of AMD 
prior to diagnosis. Therefore, the results are likely to 
generalise to a wider population and, if anything, may 
underestimate the true scale of the problem.
Our finding that those with wet AMD were twice as likely 
as those with dry AMD to seek help within 1 week provides 
a more positive picture than previous studies. Earlier 
research by Varano and colleagues reported that for 
those with wet AMD, only 23% sought help within 1 week 
of first noticing a change in vision.18 This compares with 
72% of respondents with wet AMD in the present study. 
However, Varano et al’s18 study was conducted across nine 
countries, where time to seek help may differ between 
countries due to variation in access to, and provision 
of, eye-care services, particularly as this study indicated 
delays in obtaining an appointment was a primary reason 
for delay. In addition, Sim et al10 suggested that a lack 
of awareness of AMD could account for substantial 
delays. It may be that the smaller percentage of respon-
dents delaying help seeking in this study is attributable 
to greater awareness of AMD. Although respondents 
in this study were recruited from the Macular Society, 
57% reported no prior awareness of AMD (table 1), and 
further quantitative analyses indicated no significant link 
between prior awareness of AMD and time to seek help. 
We noted, however, that qualitatively several respondents 
reported lack of awareness of AMD symptoms and risk 
factors as a reason for delayed help seeking (table 3).
Sim et al’s10 additional finding that only 37.3% of 
patients could describe AMD symptoms correctly was also 
echoed in this study as several patients listed symptoms 
not indicative of AMD, reported a lack of knowledge 
about AMD symptoms/risk factors or misattributed 
symptoms of AMD to other eye conditions (eg. cataract 
or glaucoma). This highlights the need for public and 
patient education about symptoms of AMD and how to 
distinguish these from symptoms of other eye conditions, 
particularly in an elderly population, likely to have more 
than one eye condition.
The most commonly cited reason for delay, primarily 
by those with wet AMD, of difficulty obtaining an earlier 
hospital, optometrist or GP appointment, is consistent with 
previous research that among people with eye conditions, 
including AMD (23%), a large proportion (72%) experi-
enced permanent reduction in VA due to service-related 
delays.19 Of these service-related delays, 76% were due to 
delayed follow-up appointments for monitoring, a problem 
reported primarily by patients with wet AMD in this study. 
Shared care between community optometrists and hospital 
ophthalmologists has been suggested as a possible solution 
to such delays, with optometrists monitoring more stable 
cases of wet AMD and freeing up ophthalmologists to diag-
nose and treat new cases of wet AMD more promptly.20 
Several patients in the current study, particularly with wet 
AMD, reported that they were passed between HCPs or 
referred from their optometrist to the hospital via their 
GP. This is despite RCOphth guidance since 200915 that 
optometrists should refer straight to the hospital and 
suggests that this message needs to be highlighted again 
to reduce delay, particularly as referral via the GP has been 
found to extend delay by an average of 7.5 days.10 The 
RCOphth guidelines further suggest that patients should 
be given a clear diagnosis and suggestions for treatment, 
including signposting to support services where medical 
treatment is not possible. However, in this study, 31% of 
patients reported that a diagnosis of AMD was not labelled 
in the initial consultation (by a hospital eye specialist in 
20% of cases, 23% by a GP and 57% by an optometrist), 
and 8% reported that they were told ‘nothing can be 
done’, with 42% of these patients having wet AMD. This is 
in line with previous research, which suggested only 43% 
of patients were diagnosed during their first visit.18 Delay 
in diagnosis has already been shown to be associated with 
likelihood of registration as sight impaired or severely sight 
impaired and to cause delay in accessing support services.11 
Clearly interventions are needed to improve the skills of 
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practitioners in detecting and managing AMD symptoms 
and awareness of the urgency for treatment of wet AMD. 
For several patients AMD was only detected following cata-
ract removal. Although there is consensus that cataract 
surgery does not cause AMD progression, the presence 
of co-existing cataract may mask AMD detection.21 22 The 
current study, therefore, highlights the importance of eval-
uating patients for AMD symptoms before and following 
cataract surgery.
Patient-related reasons for delayed assessment 
included patients, commonly with wet AMD, not attrib-
uting their symptoms to AMD due to lack of knowledge 
about the symptoms and risks for the condition, or that 
they did not perceive their symptoms to be urgent or 
serious, and therefore waited for their next ‘routine’ 
appointment. This highlights the need for a public 
health campaign educating the general population 
about the symptoms and risk factors for developing 
AMD and the importance of prompt help seeking with 
an urgent self-referral to eye emergency care services if 
symptoms are noticed.
In summary, although most patients sought help within 
1 week, there was a delay from symptom onset to assess-
ment for 27% and 50% of patients with wet and dry 
AMD, respectively. These are in addition to the number 
of patients whose care was delayed following their initial 
presentation to a HCP who did not refer appropriately to 
the Macular Clinic. For those with wet AMD this delay has 
been linked with poorer treatment outcomes, while with 
dry AMD the diagnostic consultation is a key time for 
providing education about how to monitor their symp-
toms for possible change to wet AMD, aiding prompt 
future help-seeking and reducing likelihood of being 
registered as sight impaired.11 A number of suggestions 
have been provided above for reducing delay, primarily 
in reference to:
 ► Interventions for example, TV/poster campaigns to 
increase general population and practitioner aware-
ness of AMD symptoms including how to detect AMD 
and the importance of early help seeking (without 
first visiting the GP).
 ► Education for newly diagnosed patients in Amsler 
grid use and ongoing monitoring for wet AMD by 
patient and practitioner, particularly following treat-
ment for other eye conditions.
 ► Signposting patients with dry/wet AMD to appro-
priate support services following the initial consulta-
tion. For example, charities can provide additional 
information to reinforce HCP advice about ongoing 
monitoring for potential signs of wet AMD and visual 
rehabilitation/counselling services to support adjust-
ment to acquired visual difficulties; such support 
services could also help patients with dry AMD under-
stand why they have not been referred for medical 
treatment. Signposting to support services is recom-
mended in the NICE guidelines for those with wet 
AMD currently12 but our findings suggest this is also 
beneficial for those with dry AMD.
Informative interventions targeting the general popu-
lation will need pilot work to ensure optimal design but 
have the potential for saving the eyesight of a substan-
tial proportion of people with wet AMD currently not 
receiving sufficiently prompt diagnosis and treatment, 
and even more people who will go on to develop treat-
able wet AMD.
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